Nuvectis Pharma, Inc. (NASDAQ:NVCT – Free Report) – HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Tuesday, August 4th. HC Wainwright also issued estimates for Nuvectis Pharma’s Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.02) EPS, FY2027 earnings at ($1.10) EPS and FY2028 earnings at ($1.24) EPS. Get Nuvectis Pharma alerts:Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. Nuvectis Pharma Company Profile(Get Free Report)Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. Featured StoriesReceive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.